Manish Dhawan

Rosiglitazone-induced granulomatous hepatitis.

Granulomatous hepatitis has many causes. Drugs are an important etiologic factor. Several oral hypoglycemic agents are available for treatment of type II diabetes. Rosiglitazone, a thiazolidinedione, is a newer agent in this class. It has not been shown to be hepatotoxic in the premarketing trials. However, a few case reports have implicated it as a cause of acute hepatocellular injury. The authors report a case of granulomatous hepatitis associated with use of rosiglitazone. Liver function tests should be done regularly to monitor patients on this medication.

Gastric-duplication cyst with an aberrant pancreatic-ductal system: an unusual cause of recurrent abdominal pain

1. Batts KP. Ischemic cholangitis. Mayo Clin Proc 1998;73:380-5. 2. Barquist ES, Goldstein N, Zinner MJ. Polyarteritis nodosa presenting as a biliary stricture. Surgery 1991;109:16-9. 3. Kasper HU, Dries V, Drebber U, et al. Florid ischemic cholangitis due to leucocytoclastic vasculitis. J Gastroenterol 2004;39:188-91. 4. Viola S, Meyer M, Fabre M, et al. Ischemic necrosis of bile ducts complicating Schonlein-Henoch purpura. Gastroenterology 1999;117:211-4. 5. Jaeger C, Mayer G, Henrich R, et al. Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow-up. Endoscopy 2006; 38:730-4.

Ocular Radiation Threshold Projection Based off of Fluoroscopy Time During ERCP

OBJECTIVES:Current international guidelines for ocular radiation exposure suggest a threshold of 20 millisieverts (mSv)/year. Although endoscopists wear lead aprons, use of protective eye wear is optional. This study was conducted to analyze the lens radiation exposure during endoscopic retrograde cholangiopancreatography (ERCP) for endoscopists to determine the time of fluoroscopy needed to warrant using lens protection during ERCP.METHODS:ERCP patients were prospectively enrolled. Indications, interventions, fluoroscopy time, dose, and attending ± fellow involvement were recorded. Radiation exposure was collected from body dosimeters and dosimeters placed between the eyes. Cumulative radiation doses were obtained at study completion and averaged over the total fluoroscopy time to determine the mSv/hour exposure.RESULTS:A total of 187 cases were included. Attendings and fellows wore lens dosimeters in 178 and 126 cases, respectively, and body dosimeters in 174 and 128 cases, respectively. Attendings and fellows wore lens dosimeters throughout 15.89 and 11.24 h of fluoroscopy, respectively. The cumulative radiation dose absorbed per lens dosimeters was 5.35 mSv for attendings and 2.55 mSv for fellows. The projected lens absorption by the body dosimeters was 19.03 mSv for attendings and 5.21 mSv for fellows. The hourly fluoroscopy lens exposure was 0.34 mSv/hour for attendings and 0.23 mSv/hour for fellows.CONCLUSIONS:The amount of fluoroscopy hours needed to reach the currently suggested lens threshold limit (20 mSv/year) was 59.41 h for attendings and 88.17 h for fellows. Radioprotective eye wear should be worn by physicians with yearly fluoroscopy times in similarly structured practices that meet or exceed these thresholds.

Rosiglitazone induced granulomatous hepatitis

Granulomatous hepatitis has many causes. Drugs are an important etiologic factor. Several oral hypoglycemic agents are available for treatment of type II diabetes. Rosiglitazone, a thiazolidinedione, is a newer agent in this class. It has not been shown to be hepatotoxic in the premarketing trials. However, a few case reports have implicated it as a cause of acute hepatocellular injury. The authors report a case of granulomatous hepatitis associated with use of rosiglitazone. Liver function tests should be done regularly to monitor patients on this medication.

Argon plasma coagulation treatment of intraductal papillary neoplasm of biliary tract: an alternative approach

re 1. A, MRCP view showing dilated common bile and hepatic ducts. B, ERCP view showing mucobilia as a filling defect that was aggressively cleared . No mass lesion was seen on occlusion cholangiogram following clearance (right). C, Fluoroscopic image of adult gastroscope in the common bile D, Endoscopic view showing the common hepatic duct and bifurcations. E, Endoscopic view showing nodularities of the cystic duct (left) with w-band imaging (right). F, Staining of biopsy specimen showing intraductal papillary neoplasm of the bile duct, gastric type. Mucinous elium-forming papillary structures also seen here (left, H&E, orig. mag. 10; right, H&E, orig. mag. 20). G, Post-argon plasma coagulation treatt of nodularities.